ProfileGDS5678 / 1428493_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 65% 63% 67% 66% 66% 66% 66% 66% 67% 66% 66% 66% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.04366
GSM967853U87-EV human glioblastoma xenograft - Control 23.9257965
GSM967854U87-EV human glioblastoma xenograft - Control 33.7722663
GSM967855U87-EV human glioblastoma xenograft - Control 44.0744867
GSM967856U87-EV human glioblastoma xenograft - Control 53.9765666
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0539866
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0566366
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0148366
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0108966
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0294867
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9979666
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0143166
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0266166
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2449769